Supplementary Online Content


**eFigure.** Decision Tree Showing the Proportion of Newborns With cCMV Infection, Symptoms at Birth, Clinical Diagnosis, and Hearing Loss at Birth or Late-Onset Hearing Loss

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure. Decision Tree Showing the Proportion of Newborns With cCMV Infection, Symptoms at Birth, Clinical Diagnosis, and Hearing Loss at Birth or Late-Onset Hearing Loss

Hearing loss at birth or late-onset hearing loss is either mild-moderate (M-M) or severe-profound (S-P) under the 3 scenarios: base case (no cCMV screening); universal newborn cCMV screening; and targeted newborn cCMV screening.
Universal screening

*In measuring the net impact of universal screening, it is assumed that 25% of all symptomatic cases would have been clinically diagnosed without the screening.
Targeted screening

*In measuring the net impact of targeted screening, it is assumed that 25% of the symptomatic cases identified with targeted screening would have been clinically diagnosed without the screening.